Two Different Concentrations of Topical Levofloxacin for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Keratitis
- PMID: 26348840
- DOI: 10.1089/jop.2015.0026
Two Different Concentrations of Topical Levofloxacin for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Keratitis
Abstract
Purpose: To compare the efficacy of topical 1.5% and 0.5% levofloxacin (LVFX) for the treatment of multidrug-resistant Pseudomonas aeruginosa (MDRP) keratitis in rabbits.
Methods: In a rabbit eye, we produced an MDRP keratitis model by excising a 2-mm circular disc of the cornea up to a depth of one-half of the stromal layer and inoculated an MDRP strain into the corneal concavity. Nine hours after inoculation and after confirming that MDRP keratitis had developed, we treated the eyes topically with 0.5% levofloxacin, 1.5% levofloxacin, or phosphate-buffered saline (PBS) every 6 h until 57 h postinfection. The infected eyes were evaluated by clinical score, histopathological examination, and viable bacterial count (colony forming units).
Results: In the MDRP keratitis model, clinical score was significantly lower in 0.5% and 1.5% levofloxacin-treated groups than in PBS-treated group and was the lowest in 1.5% levofloxacin-treated group. Histopathological examination showed maintenance of corneal translucency and little influx of polymorphonuclear neutrophils in 1.5% levofloxacin-treated group. Viable bacterial count in the infected cornea was significantly lower in 0.5% levofloxacin-treated group compared with PBS-treated group, while no viable bacteria were detected in 1.5% levofloxacin-treated group.
Conclusions: Using our MDRP keratitis model, we showed that topical 0.5% levofloxacin is not adequately effective, while 1.5% levofloxacin is efficacious in controlling MDRP keratitis.
Similar articles
-
In vivo challenging of polymyxins and levofloxacin eye drop against multidrug-resistant Pseudomonas aeruginosa keratitis.J Infect Chemother. 2014 Jun;20(6):343-9. doi: 10.1016/j.jiac.2013.10.015. Epub 2013 Dec 11. J Infect Chemother. 2014. PMID: 24726376
-
Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.Cornea. 2011 Jan;30(1):83-90. doi: 10.1097/ICO.0b013e3181e2f0f3. Cornea. 2011. PMID: 20847656
-
A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.Am J Ophthalmol. 2004 Aug;138(2):226-30. doi: 10.1016/j.ajo.2004.03.016. Am J Ophthalmol. 2004. PMID: 15289131
-
Pharmacokinetic considerations in the treatment of bacterial keratitis.Clin Pharmacokinet. 1994 Aug;27(2):129-49. doi: 10.2165/00003088-199427020-00005. Clin Pharmacokinet. 1994. PMID: 7955776 Review.
-
Experimental Pseudomonas keratitis.Trans Am Ophthalmol Soc. 1981;79:541-624. Trans Am Ophthalmol Soc. 1981. PMID: 6805124 Free PMC article. Review. No abstract available.
Cited by
-
The Role of Pseudomonas aeruginosa in the Pathogenesis of Corneal Ulcer, Its Associated Virulence Factors, and Suggested Novel Treatment Approaches.Pharmaceutics. 2024 Aug 16;16(8):1074. doi: 10.3390/pharmaceutics16081074. Pharmaceutics. 2024. PMID: 39204419 Free PMC article. Review.
-
The antibiotic resistance profiles of Pseudomonas aeruginosa in the Asia Cornea Society Infectious Keratitis Study.Int Ophthalmol. 2024 Aug 31;44(1):361. doi: 10.1007/s10792-024-03270-y. Int Ophthalmol. 2024. PMID: 39215853 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical